| 【Company Research】Akeso (9926 HK) - Eyes on the detailed head-to-head data of AK112 at WCLC in Sep |
| 【Company Research】PICC P&C (2328 HK) - CoR sequentially improved turning to positive 2Q net profit growth; first interim dividend in place |
| 【Company Research】DPC Dash (1405 HK) - Prudence guidance with solid fundamentals |
| 【Company Research】Baozun (BZUN US) - 2Q loss reduction trend better than expectation |
| 【Company Research】BYDE (285 HK) - Positive on multiple growth drivers ahead despite near-term drags from Jabil integration |
| 【Company Research】AK Medical (1789 HK) - Resilient performance in 1H24, expecting recovery in 2H24 |
| 【Company Research】Salesforce (CRM US) - cRPO growth reaccelerates; eyes on new AI product launch |
| 【Company Research】Innovent Biologics (1801 HK) - 2025 EBITDA breakeven goal unchanged |
| 【Company Research】SANY International (631 HK) - Scale-down of solar power expansion plan a positive move |
| 【Company Research】Tigermed (300347 CH) - Order growth in 1H24 signals reduced uncertainties in demand recovery |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
